The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
ApexOnco Front Page
Recent articles
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
Posters and mini-orals include another VEGF bispecific.
Interius, one of the most advanced players, will cost $350m.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Summit and Nuvalent have scored prized plenary spots.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Inclacumab fails, and osivelotor is on hold.
